Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by PureTech Health plc

< Previous 1 2 3 4 Next >
PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Announces Annual Results for Year Ended December 31, 2023
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Health: Notice of Results
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Proposes $100 Million Capital Return
From PureTech Health plc
Via Business Wire
Tickers PRTC
Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech to Present at Two Upcoming Investor Conferences
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan
From PureTech Health plc
Via Business Wire
Tickers AKLI PRTC
PureTech to Present at 42nd Annual J.P. Morgan Healthcare Conference
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Year End Update and Outlook for 2024
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
From PureTech Health plc
Via Business Wire
Tickers KRTX PRTC
PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech's LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy Volunteers
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech to Present at Two Upcoming Investor Conferences
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults at CHEST Annual Meeting
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Vedanta Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of VE202 for the Treatment of Ulcerative Colitis and Receives Fast Track Designation
From PureTech Health plc
Via Business Wire
Tickers PRTC
KarXT, invented at PureTech, submitted for FDA Approval in Schizophrenia
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Announces the Appointment of Robert Lyne as Chief Portfolio Officer
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Health plc – Half-Year Report
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Health: Notice of Half-Yearly Results
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Awarded up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-associated Tremor/Ataxia Syndrome
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Initiates Phase 2a Clinical Trial of LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders
From PureTech Health plc
Via Business Wire
Tickers PRTC
Results of PureTech's Annual General Meeting
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech to Present at the Jefferies Healthcare Conference
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Akili Announces Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based Therapeutic
From PureTech Health plc
Via Business Wire
Tickers AKLI PRTC
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.